MedTrace Logo

Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes

NCT04633551 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-09-21

Study results available
· View outcomes & findings →

Summary

Women who had an adverse pregnancy outcome (APO), such as preeclampsia, preterm birth, or gestational diabetes, have a higher risk for heart disease. Some of the extra risk for heart disease after APOs is thought to be caused by inflammation. Investigators will randomize women who had an APO in the past 3 years to receive an anti-inflammatory supplement or serve as a time control. Investigators will compare blood pressure, arterial stiffness, blood vessel reactivity, and blood markers of inflammation between women who did and did not receive the supplement. Investigators will determine women's attitudes about taking a dietary supplement and measure whether the participants who receive the supplement take all or most of the doses.

Conditions

  • Pre-Eclampsia
  • Pre-Term
  • Intrauterine Growth Restriction
  • Hypertension in Pregnancy

Interventions

DIETARY_SUPPLEMENT

Anti-inflammatory supplement

commercially available combination of curcumin, quercitin, resveratrol, and green tea

Sponsors & Collaborators

  • University of South Carolina

    lead OTHER

Principal Investigators

  • Abbi Lane-Cordova, PhD · University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-06-30
Completion
2022-05-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04633551 on ClinicalTrials.gov